Scandonest (Mepivacaine 3%): Uses, Dosage & Side Effects

What Is Scandonest (Mepivacaine) and What Is It Used For?

Scandonest is a brand name for mepivacaine hydrochloride, a synthetic local anesthetic that belongs to the amide class of local anesthetics. Mepivacaine was first synthesized by the Swedish chemist A.F. Ekenstam in 1956 and was introduced into clinical practice in 1960. Its chemical structure is similar to that of lidocaine but with a different substitution on the amine nitrogen, giving it distinct pharmacological properties, most notably a lower intrinsic vasodilatory effect on blood vessels near the injection site. Scandonest is produced by Septodont, a French pharmaceutical manufacturer specializing in dental products, and is distributed worldwide as one of the most commonly used dental local anesthetics.

Like all local anesthetics, mepivacaine works by reversibly blocking the generation and conduction of nerve impulses in the area surrounding the injection site. Specifically, it binds to and inhibits voltage-gated sodium channels on the intracellular side of nerve cell membranes, preventing the influx of sodium ions that is necessary for the generation of action potentials. This produces a temporary loss of sensation (anesthesia) in the tissues supplied by the affected nerves, allowing painless dental and surgical procedures to be performed. Because the sodium channel blockade is reversible and the drug is eventually metabolized and cleared from the tissue, normal nerve function returns within a predictable period.

The Scandonest 3% formulation (30 mg/ml) is distinctive in that it contains no vasoconstrictor such as epinephrine (adrenaline) or felypressin. Most dental local anesthetics include a vasoconstrictor to slow the absorption of the anesthetic from the injection site, thereby prolonging the duration of anesthesia and reducing systemic toxicity. Mepivacaine, however, has an inherently lower vasodilatory effect than other amide-type anesthetics, meaning that it does not cause significant dilation of local blood vessels. This allows the drug to remain at the injection site long enough to produce adequate anesthesia for short dental procedures without requiring a vasoconstrictor.

The principal clinical uses of Scandonest 3% (plain mepivacaine) include:

• Dental infiltration anesthesia: Injection of Scandonest near the apex of a tooth (buccal or palatal infiltration) to produce localized anesthesia of a single tooth or small group of teeth. This technique is widely used for restorative dentistry (fillings), extractions of single teeth, and minor periodontal procedures.
• Regional nerve block anesthesia: Injection of Scandonest near a major dental nerve trunk to anesthetize the tissues supplied by that nerve. Common blocks performed with Scandonest include the inferior alveolar nerve block (anesthetizing the mandibular teeth and associated soft tissues on one side), the posterior superior alveolar nerve block (for maxillary molars), and the mental nerve block (for the lower lip and chin).
• Short dental procedures: Because the duration of pulpal anesthesia is relatively short (approximately 20 to 40 minutes), Scandonest 3% is particularly well suited to brief procedures such as single-tooth fillings, simple extractions, suture removal, scaling in sensitive patients, and procedures in children where prolonged soft-tissue numbness could lead to self-inflicted bite injuries.
• Patients with contraindications to vasoconstrictors: Scandonest 3% is the anesthetic of choice for patients in whom epinephrine should be avoided. These include patients with unstable angina, recent myocardial infarction (within the previous 3 to 6 months), severe uncontrolled hypertension, uncontrolled hyperthyroidism, pheochromocytoma, and those taking monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, or certain other medications with known epinephrine interactions.
• Oral surgical procedures: Used for surgical extractions, periapical surgery, minor soft tissue surgery of the oral cavity, and as a component of balanced anesthesia in conjunction with sedation techniques.

While the primary market for Scandonest is dentistry, mepivacaine is also used outside dentistry in some jurisdictions for infiltration anesthesia, peripheral nerve blocks, and epidural anesthesia in higher concentrations (commonly 1% or 2% solutions). However, the 3% dental cartridge formulation marketed under the Scandonest brand is specifically intended for intraoral use by dental professionals and is not typically used for medical (non-dental) anesthesia. Other commercial brand names for mepivacaine internationally include Carbocaine, Polocaine, Mepivastesin, and Isocaine.

Since its introduction, mepivacaine has accumulated an extensive evidence base supporting its efficacy and safety profile. Modern systematic reviews and clinical trials consistently demonstrate that mepivacaine 3% plain is comparable to lidocaine 2% with epinephrine for short dental procedures, with a faster metabolism profile and a safety advantage in patients with cardiovascular contraindications to vasoconstrictors. It remains a first-choice anesthetic in many dental practices globally and is considered a cornerstone drug in the dental anesthetic armamentarium.

What Should You Know Before Taking Scandonest?

Contraindications

There are specific situations in which Scandonest must not be administered. Understanding these absolute contraindications is essential for patient safety and is the responsibility of the prescribing dentist or physician.

• Known hypersensitivity to mepivacaine: Do not use Scandonest if you have a documented allergy (hypersensitivity) to mepivacaine hydrochloride or any of the excipients in the product. True allergy to amide-type local anesthetics is extremely rare (representing less than 1% of all adverse reactions attributed to local anesthetics), but when it occurs, reactions can range from localized dermatitis to life-threatening anaphylaxis.
• Allergy to other amide-type local anesthetics: If you have a confirmed allergy to other amide-type local anesthetics such as lidocaine, bupivacaine, prilocaine, ropivacaine, or articaine, you should not receive mepivacaine, as cross-reactivity within the amide class is possible. In such situations, an ester-type local anesthetic may be considered, although these carry their own risk of allergic reactions.
• Severe cardiac conduction disturbances: Mepivacaine, like other local anesthetics, can depress cardiac conduction. It is contraindicated in patients with severe unstable heart block (second or third degree atrioventricular block not managed by a pacemaker), severe bradyarrhythmia, or severe uncontrolled heart failure where even small doses of a sodium channel blocker could precipitate cardiovascular instability.
• Acute porphyria: Mepivacaine is potentially porphyrinogenic and may trigger acute attacks in susceptible individuals. It should be avoided in patients with a personal or family history of acute intermittent porphyria, variegate porphyria, or hereditary coproporphyria.
• Infection at the injection site: Injection of local anesthetic into an area of acute infection (abscess, cellulitis) is relatively contraindicated because the acidic environment of infected tissue reduces the effectiveness of the anesthetic and may disseminate the infection. Alternative anesthetic techniques (such as nerve blocks injected at a distance from the infected site) may be preferred.

Warnings and Precautions

You should inform your dentist or physician before receiving Scandonest if any of the following conditions apply to you:

• Cardiovascular disease: Mepivacaine can depress myocardial conduction and contractility. Caution is required in patients with ischemic heart disease, heart failure, conduction disturbances (heart block), severe hypertension, or significant arrhythmias. Although mepivacaine is often the preferred dental anesthetic in cardiac patients (because it avoids the cardiovascular effects of epinephrine), careful dose adjustment and patient monitoring remain essential.
• Liver disease: Mepivacaine is metabolized primarily in the liver by cytochrome P450 enzymes. Patients with significant hepatic impairment (cirrhosis, severe hepatitis) may have reduced clearance of mepivacaine, leading to elevated plasma concentrations and an increased risk of systemic toxicity. Dose reduction is typically required.
• Kidney disease: Although mepivacaine itself is primarily hepatically metabolized, its metabolites are excreted in the urine. Patients with severe renal impairment may accumulate these metabolites with repeated dosing. Dose adjustment may be appropriate.
• Methemoglobinemia: Mepivacaine may, in rare cases, contribute to methemoglobinemia, a condition in which hemoglobin is unable to carry oxygen effectively. Patients with congenital methemoglobinemia or glucose-6-phosphate dehydrogenase (G6PD) deficiency may be at increased risk.
• Elderly or debilitated patients: Older adults may be more sensitive to the effects of local anesthetics due to age-related reductions in hepatic blood flow, liver enzyme activity, and plasma protein binding. Smaller doses are usually appropriate.
• Epilepsy or seizure disorders: Local anesthetic systemic toxicity can lower the seizure threshold. In patients with known seizure disorders, particular care is needed to avoid exceeding the maximum recommended dose.
• Myasthenia gravis: Local anesthetics can potentially worsen symptoms of myasthenia gravis, although this is more commonly associated with ester-type anesthetics. Caution is advised.

Pregnancy and Breastfeeding

If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, inform your dentist or physician before receiving Scandonest.

Pregnancy: The safety of mepivacaine during pregnancy has not been definitively established. Mepivacaine crosses the placenta and can reach the fetal circulation. Animal studies have not consistently demonstrated teratogenic effects, but fetal bradycardia has been observed following maternal administration of mepivacaine in the setting of regional obstetric anesthesia. For routine dental care, elective procedures are typically deferred until after delivery. When dental treatment cannot be postponed, lidocaine with epinephrine is generally considered the first-choice local anesthetic during pregnancy because of its longer track record and more extensive safety data in pregnant women. If Scandonest is used during pregnancy, the lowest effective dose should be administered, and the dentist should balance the risks and benefits on an individual basis. In particular, the third trimester should be approached with caution because of the risk of fetal bradycardia with mepivacaine.

Breastfeeding: Mepivacaine is excreted into breast milk in small amounts, but the quantities involved are considered clinically insignificant at the small doses used for dental anesthesia. After a single dental procedure with Scandonest, breastfeeding can generally be resumed immediately; interruption of breastfeeding is not typically required. However, it is always prudent to inform your dentist and, if uncertain, to consult your physician or pharmacist.

Allergy and Hypersensitivity Considerations

True IgE-mediated allergy to amide-type local anesthetics, including mepivacaine, is extremely rare. Most reported "allergies" to local anesthetics are in fact due to other causes, such as:

• Vasovagal reactions (fainting, pallor, sweating, bradycardia) triggered by anxiety, pain, or the sight of the needle.
• Sympathetic responses to epinephrine-containing anesthetics (tachycardia, tremor, anxiety) — not applicable to plain Scandonest 3%, but often confused with allergic reactions.
• Inadvertent intravascular injection producing symptoms of systemic toxicity (dizziness, tremor, visual disturbance).
• Reactions to preservatives such as metabisulfite (which is present in epinephrine-containing anesthetics, but not in plain mepivacaine formulations) or parabens.

Patients who report a previous "allergic reaction" to a dental local anesthetic should be referred for formal allergy evaluation by an allergist experienced in local anesthetic testing. In many cases, skin prick testing and intradermal testing (followed by graded challenge if negative) will rule out true allergy, allowing the patient to receive local anesthesia safely in the future.

Driving and Operating Machinery

Scandonest, when used at recommended doses for dental procedures, does not typically impair the ability to drive or operate machinery. The drug acts locally and does not produce significant central nervous system effects at therapeutic doses. However, the soft-tissue numbness that follows dental anesthesia may cause difficulty with tasks such as eating and speaking for 2 to 3 hours post-procedure, and some patients experience transient dizziness or lightheadedness after their dental appointment. If a patient received concurrent sedation or premedication, driving should be avoided until full recovery.

How Does Scandonest Interact with Other Drugs?

Drug interactions involving mepivacaine are most clinically relevant when higher doses are used, when multiple local anesthetics are administered concurrently, or when the patient is taking medications that affect hepatic drug metabolism or cardiovascular function. For the relatively small doses typically used in routine dental anesthesia, serious interactions are uncommon but should nonetheless be considered. Always inform your dentist, physician, or pharmacist about all prescription medications, over-the-counter drugs, herbal remedies, and dietary supplements you are taking.

Major Interactions

Minor Interactions

It is particularly important to note that because Scandonest 3% contains no epinephrine, the well-known interactions between epinephrine-containing local anesthetics and certain drugs (such as monoamine oxidase inhibitors, tricyclic antidepressants, and non-selective beta-blockers) do not apply. This is one of the principal reasons why plain mepivacaine is often selected for patients taking these medications; it provides the anesthesia needed for dental treatment without the cardiovascular complications that can occur when epinephrine is combined with them.

What Is the Correct Dosage of Scandonest?

Scandonest dosing varies according to the nature and duration of the procedure, the injection technique used, the patient's medical status, age, and body weight. The following recommendations are based on international guidelines including the EMA SmPC, FDA-approved labeling, BNF, and clinical guidelines from the American Dental Association (ADA). Your dentist will determine the exact dose required for your specific procedure.

Scandonest 3% is supplied in standard dental cartridges of 1.7 ml or 1.8 ml, delivering approximately 51 to 54 mg of mepivacaine hydrochloride per cartridge. One cartridge is typically sufficient for single-tooth infiltration anesthesia in most adults. For regional nerve blocks or procedures involving multiple teeth, one to two cartridges may be required.

Adults

Children

Scandonest 3% is approved for use in children aged 4 years and older. In pediatric patients, dosing must be carefully calculated based on body weight, and conservative dosing is essential because children are more susceptible to systemic local anesthetic toxicity than adults (due to smaller blood volumes, immature hepatic metabolism, and reduced plasma protein binding). Children are also at elevated risk of self-inflicted bite injuries from prolonged soft-tissue anesthesia and may require closer post-procedure supervision.

The maximum recommended pediatric dose of mepivacaine is 4.4 mg/kg body weight, not to exceed a total of 300 mg. However, because of the additional safety concerns, many pediatric dentists use even more conservative upper limits of 3 mg/kg. A typical 20 kg child can safely receive up to approximately 1.5 to 2 cartridges of Scandonest 3%, but most pediatric procedures can be performed with a single half-cartridge (0.9 ml) or less. Scandonest is not recommended for children under 4 years of age or for those weighing less than 15 kg due to insufficient safety data in this population.

Elderly Patients

Elderly patients are more sensitive to local anesthetics due to age-related changes in drug disposition. With advancing age, hepatic blood flow decreases, liver enzyme activity may be reduced, plasma protein binding declines, and body composition shifts (reduced lean mass, increased fat). These changes can reduce mepivacaine clearance by 30 to 50%. In addition, many elderly patients have coexisting cardiovascular or neurological conditions that increase their susceptibility to the toxic effects of local anesthetics. The dose of Scandonest should be reduced by 25 to 50% in elderly patients, with particular caution if there is evidence of cardiac disease, hepatic impairment, or general debility.

Missed Dose

Because Scandonest is administered only by a healthcare professional during a dental or surgical procedure, a "missed dose" in the traditional sense is not applicable. The drug is not self-administered by patients. If a planned dental appointment is missed, simply reschedule with your dentist; no catch-up dosing is required.

Overdose

Systemic toxicity from mepivacaine most commonly results from inadvertent intravascular injection (where the drug is injected directly into a blood vessel) rather than from absolute overdose. Aspiration before injection is the single most important preventive measure. Other causes of systemic toxicity include repeated dosing exceeding the maximum safe total, injection into highly vascular tissues with rapid absorption, and use in patients with reduced clearance (hepatic impairment, elderly, or debilitated patients).

The progression of local anesthetic systemic toxicity follows a characteristic pattern. Early central nervous system (CNS) symptoms include perioral numbness and tingling, a metallic taste, tinnitus, dizziness, lightheadedness, anxiety, restlessness, and auditory disturbances. As plasma concentrations rise, intermediate symptoms develop, including visual disturbances, slurred speech, tremor, muscle fasciculation, euphoria, and confusion. Severe toxicity manifests as generalized tonic-clonic seizures, followed by central nervous system depression (drowsiness, respiratory depression, coma). Cardiovascular toxicity is a late and ominous sign, presenting as bradycardia, hypotension, conduction disturbances, ventricular arrhythmias, and in extreme cases, cardiovascular collapse and cardiac arrest.

Management of local anesthetic systemic toxicity follows established emergency protocols: call for help immediately, manage the airway and breathing (secure airway, deliver 100% oxygen), manage seizures with benzodiazepines (intravenous midazolam or lorazepam), support the circulation with fluids and vasopressors as needed, and administer 20% lipid emulsion intravenously as a 1.5 ml/kg bolus followed by infusion of 0.25 ml/kg/min. Lipid emulsion binds circulating free local anesthetic and facilitates redistribution away from cardiac and neural tissue, and has transformed the management of severe local anesthetic toxicity.

What Are the Side Effects of Scandonest?

Like all medications, Scandonest can cause side effects, although not everyone experiences them. The majority of side effects associated with dental local anesthetic injections are mild, localized, and self-limiting. Serious adverse effects are almost always related to excessive absorption leading to systemic toxicity, inadvertent intravascular injection, rare allergic reactions, or injection-related trauma. The following classification is based on the manufacturer's product information, regulatory authorities (EMA, FDA), and post-marketing surveillance data.

It is important to distinguish between the expected local numbing effect of Scandonest and symptoms of systemic toxicity. The intended effect of the drug is localized anesthesia of the teeth and soft tissues in the area of injection, which is normal and desired. However, if numbness spreads well beyond the injection area (particularly circumoral or extending to the opposite side), or if any of the systemic symptoms listed above occur, immediate medical evaluation is needed.

Reporting adverse drug reactions helps regulatory authorities monitor the ongoing safety of medicines. If you experience any adverse effects while receiving Scandonest, even if they are not listed here, you can report them directly to your national pharmacovigilance authority (e.g., the MHRA Yellow Card scheme in the UK, the FDA MedWatch program in the US, or the EMA EudraVigilance system in Europe) or through your dentist.

How Should You Store Scandonest?

Scandonest is a professional-use dental medication that is not dispensed directly to patients. Its storage is the responsibility of the dental practice and its staff. The following guidelines apply to the dental professional and the practice where Scandonest is stored and used:

• Storage temperature: Store Scandonest dental cartridges at controlled room temperature, below 25°C (77°F). Do not refrigerate unless specifically indicated in the product information, and never freeze the cartridges. Freezing can damage the cartridge and alter the drug's effectiveness.
• Protection from light: Store cartridges in their original packaging, which protects the solution from light exposure. Prolonged exposure to light can cause degradation of the active ingredient.
• Physical inspection: Before each use, inspect the cartridge for damage, discoloration, particulate matter, or leakage. Do not use cartridges that are cracked, broken, or contain visible particles. The solution should be clear and colorless to pale yellow; do not use if the solution appears cloudy or discolored.
• Single-patient use: Each Scandonest cartridge is intended for single-patient use. Any unused solution remaining in a partially used cartridge must be discarded after the procedure and must not be reused for another patient, to prevent cross-contamination and in accordance with infection control standards.
• Expiry date: Do not use Scandonest after the expiry date printed on the cartridge or carton. The expiry date refers to the last day of the stated month. Expired local anesthetics may have reduced potency or, in rare cases, altered safety characteristics.
• Disposal: Used cartridges, needles, and other contaminated materials must be disposed of in accordance with local regulations for medical waste and sharps disposal. Do not dispose of cartridges in household waste or wastewater.
• Security: As a prescription drug, Scandonest should be stored in a secure location accessible only to authorized dental personnel.

Patients do not need to take any storage-related actions because Scandonest is administered in a clinical setting and is not dispensed for home use. Any discarded or unused cartridges remain the responsibility of the dental practice and should be handled according to their clinical waste management protocols.

What Does Scandonest Contain?

Scandonest 3% contains mepivacaine hydrochloride as the active pharmaceutical ingredient, formulated as a sterile isotonic solution for injection. The formulation is simple and deliberately minimal, which contributes to its low potential for allergic reactions compared with some other dental local anesthetics.

Active Ingredient

Each 1 ml of Scandonest 3% solution contains 30 mg of mepivacaine hydrochloride (equivalent to approximately 26.3 mg of mepivacaine base). A standard dental cartridge of 1.7 ml contains approximately 51 mg of mepivacaine hydrochloride; a 1.8 ml cartridge contains approximately 54 mg. The specific chemical form used is mepivacaine hydrochloride monohydrate (CAS number: 1722-62-9), with a molecular formula of C₅H₂₂N₂O·HCl·H₂O and a molecular weight of 282.81 g/mol.

Inactive Ingredients (Excipients)

The inactive ingredients in Scandonest 3% typically include:

• Sodium chloride: Added to adjust the solution to isotonicity with physiological tissues, reducing irritation at the injection site.
• Sodium hydroxide and/or hydrochloric acid: Used in small quantities to adjust the pH of the solution to approximately 5.5 to 6.5, which is optimal for stability of the active ingredient while remaining tolerable to tissues.
• Water for injection: The sterile aqueous vehicle in which all other ingredients are dissolved.

Appearance and Packaging

Appearance: Scandonest 3% is a sterile, clear, colorless to pale yellow aqueous solution. The solution should be free of visible particulate matter. Any cartridge containing cloudy, discolored, or particulate-containing solution should be discarded.

Packaging: Scandonest 3% is supplied in standard dental cartridges of 1.7 ml or 1.8 ml, typically packaged in sealed blisters or cartons containing 50 or 100 cartridges. The cartridges are designed for use with standard dental aspirating syringes. The plunger is usually silicone-coated to minimize adverse reactions, and the cartridge diaphragm (through which the needle passes) is made of bromobutyl or similar rubber that is typically latex-free in modern products. Pack sizes and exact configurations may vary by country and distributor.

Related Mepivacaine Formulations

In addition to the 3% plain formulation covered in this article, mepivacaine is also available in other strengths and combinations, sometimes under the Scandonest brand name and sometimes as other products:

• Scandonest 2% Special: Contains mepivacaine 20 mg/ml with adrenaline (epinephrine) 1:100,000 as a vasoconstrictor. Provides longer duration of pulpal anesthesia (approximately 60 to 90 minutes) and is used for longer dental procedures. Available in some markets but not all.
• Scandonest 2% NA: Contains mepivacaine 20 mg/ml with noradrenaline (norepinephrine) 1:100,000. An alternative vasoconstrictor formulation; availability varies by country.
• Carbocaine: An alternative brand name for mepivacaine, available in 3% plain and 2% with levonordefrin formulations.
• Polocaine: Another brand name for mepivacaine, typically supplied as 3% plain or 2% with levonordefrin.

The marketing authorization holder for Scandonest is Septodont, headquartered in Saint-Maur-des-Fossés, France. Septodont is a global manufacturer specializing in dental pharmaceuticals and distributes Scandonest worldwide. Always refer to the current product labeling and summary of product characteristics for the most up-to-date information on ingredients, pack sizes, and availability in your country.